12:00 AM
 | 
Mar 14, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ATB-346: Phase II start

This month, Antibe will begin an open-label, Canadian Phase II trial to evaluate once-daily 250 mg oral ATB-346...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >